NEW YORK, Sept. 17 — EuroProteome announced today that it has secured €9.5 million in a financing round. The Hennigsdorf, Germany-based company, which calls itself a "human cancer proteomiucs company," is developing clinical tools for early diagnostics, prognostics, and patient-specific therapeutics and immune therapeutics for the treatment of epithelial cancers. The round was led by German VC firms Earlybird Venture Capital and Heidelberg Innovation. Nextech Venture and Aventic Partners, both of Zurich, also contributed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.